OncoCyte (OCX) Competitors $3.07 +0.13 (+4.42%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$3.08 +0.01 (+0.16%) As of 05/21/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCX vs. ARCT, HRTX, SEPN, BNTC, FULC, ATYR, ATAI, ACB, AQST, and CMPXShould you be buying OncoCyte stock or one of its competitors? The main competitors of OncoCyte include Arcturus Therapeutics (ARCT), Heron Therapeutics (HRTX), Septerna (SEPN), Benitec Biopharma (BNTC), Fulcrum Therapeutics (FULC), Atyr PHARMA (ATYR), Atai Life Sciences (ATAI), Aurora Cannabis (ACB), Aquestive Therapeutics (AQST), and Compass Therapeutics (CMPX). These companies are all part of the "pharmaceutical products" industry. OncoCyte vs. Arcturus Therapeutics Heron Therapeutics Septerna Benitec Biopharma Fulcrum Therapeutics Atyr PHARMA Atai Life Sciences Aurora Cannabis Aquestive Therapeutics Compass Therapeutics OncoCyte (NASDAQ:OCX) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, community ranking, risk, earnings and media sentiment. Which has preferable valuation and earnings, OCX or ARCT? OncoCyte has higher earnings, but lower revenue than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than OncoCyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncoCyte$3.84M22.85-$27.78M-$3.53-0.87Arcturus Therapeutics$131.27M2.51-$29.73M-$2.53-4.80 Does the media prefer OCX or ARCT? In the previous week, Arcturus Therapeutics had 8 more articles in the media than OncoCyte. MarketBeat recorded 14 mentions for Arcturus Therapeutics and 6 mentions for OncoCyte. Arcturus Therapeutics' average media sentiment score of 0.60 beat OncoCyte's score of 0.52 indicating that Arcturus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OncoCyte 0 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcturus Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor OCX or ARCT? Arcturus Therapeutics received 436 more outperform votes than OncoCyte when rated by MarketBeat users. Likewise, 66.47% of users gave Arcturus Therapeutics an outperform vote while only 12.07% of users gave OncoCyte an outperform vote. CompanyUnderperformOutperformOncoCyteOutperform Votes1412.07%Underperform Votes10287.93% Arcturus TherapeuticsOutperform Votes45066.47% Underperform Votes22733.53% Is OCX or ARCT more profitable? Arcturus Therapeutics has a net margin of -36.39% compared to OncoCyte's net margin of -6,122.29%. Arcturus Therapeutics' return on equity of -22.39% beat OncoCyte's return on equity.Company Net Margins Return on Equity Return on Assets OncoCyte-6,122.29% -269.32% -59.71% Arcturus Therapeutics -36.39%-22.39%-14.81% Which has more volatility and risk, OCX or ARCT? OncoCyte has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.36, meaning that its share price is 136% more volatile than the S&P 500. Do analysts recommend OCX or ARCT? OncoCyte presently has a consensus target price of $5.42, suggesting a potential upside of 76.44%. Arcturus Therapeutics has a consensus target price of $57.80, suggesting a potential upside of 375.72%. Given Arcturus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Arcturus Therapeutics is more favorable than OncoCyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OncoCyte 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Arcturus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Do insiders and institutionals have more ownership in OCX or ARCT? 55.3% of OncoCyte shares are owned by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are owned by institutional investors. 1.6% of OncoCyte shares are owned by insiders. Comparatively, 16.6% of Arcturus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryArcturus Therapeutics beats OncoCyte on 16 of the 19 factors compared between the two stocks. Get OncoCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCX vs. The Competition Export to ExcelMetricOncoCyteDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$87.80M$2.61B$5.37B$8.39BDividend YieldN/A0.73%5.22%4.10%P/E Ratio-0.877.4326.7719.71Price / Sales22.8535.86393.17117.39Price / CashN/A15.7538.2534.62Price / Book1.245.546.794.50Net Income-$27.78M-$65.73M$3.23B$248.18M7 Day Performance10.04%0.61%1.53%0.20%1 Month Performance5.14%3.53%10.06%12.37%1 Year Performance5.50%-15.77%16.74%7.04% OncoCyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCXOncoCyte2.414 of 5 stars$3.07+4.4%$5.42+76.4%+8.9%$87.80M$3.84M-0.87120Analyst ForecastGap DownARCTArcturus Therapeutics2.9267 of 5 stars$11.59+5.6%$59.20+410.8%-59.3%$314.33M$138.39M-5.22180HRTXHeron Therapeutics3.8615 of 5 stars$2.05-2.8%$5.50+168.3%-45.3%$312.76M$148.52M-11.39300Positive NewsSEPNSepterna2.0583 of 5 stars$6.98+4.3%$33.00+372.8%N/A$310.72M$1.08M0.00N/AEarnings ReportAnalyst RevisionBNTCBenitec Biopharma2.4171 of 5 stars$13.14-3.6%$24.71+88.1%+42.3%$308.15M$80,000.00-8.7020News CoverageAnalyst ForecastAnalyst RevisionFULCFulcrum Therapeutics0.7844 of 5 stars$5.68+5.8%$8.63+51.8%-18.2%$306.60M$80M-18.32100ATYRAtyr PHARMA2.8106 of 5 stars$3.24-1.2%$18.60+474.1%N/A$288.37M$235,000.00-3.4553Analyst ForecastATAIAtai Life Sciences2.3356 of 5 stars$1.44+3.6%$10.50+629.2%+13.7%$287.71M$308,000.00-1.7880News CoverageAnalyst ForecastGap DownACBAurora Cannabis0.6189 of 5 stars$5.06+4.3%N/A-26.8%$284.44M$320.81M101.221,340AQSTAquestive Therapeutics1.3053 of 5 stars$2.85+2.2%$10.67+274.3%-28.6%$283.07M$57.56M-6.33160Analyst RevisionGap DownCMPXCompass Therapeutics3.678 of 5 stars$2.01+10.4%$13.13+553.0%+28.8%$277.95M$850,000.00-5.4320 Related Companies and Tools Related Companies Arcturus Therapeutics Alternatives Heron Therapeutics Alternatives Septerna Alternatives Benitec Biopharma Alternatives Fulcrum Therapeutics Alternatives Atyr PHARMA Alternatives Atai Life Sciences Alternatives Aurora Cannabis Alternatives Aquestive Therapeutics Alternatives Compass Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredExclusive Offer: Target 100% Returns NowBrace yourself–this may come as a shock. It turns out that you may not have to wait decades to turn a small...ProsperityPub | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoCyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share OncoCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OCX Stock Free OCX Stock Alerts